VTGN stock news · Vistagen Therapeutics, Inc.
Get alerts for VTGN
Follow Vistagen Therapeutics, Inc. (VTGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VTGNVistagen Therapeutics, Inc. says it has a new company presentation starting September 25, 2026.
NeutralVistagen filed an 8-K attaching a September 2026 corporate presentation; the filing contains no new clinical or financial facts, so we view it as neutral for VTGN.
On Thursday, 12 health care stocks changed a lot during the day.
NeutralVistagen's shares declined to $0.30 in the session, but with no accompanying company news, this report does not change the company's view.
Vistagen Therapeutics, Inc. shares news about important events and financial details.
NeutralVistagen filed an 8-K noting Other Events and exhibits. The filing gives no detail, so it does not change the company view.
An analyst warns to be careful with Vistagen after new anxiety study results.
NeutralVistagen said PALISADE-4 missed its main goal, while its open-label extension showed safety and symptom gains; this leaves the story neutral for Vistagen.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralVistagen Therapeutics shares rose 55.92% pre-market to $0.39, but the piece only lists price moves and adds no company-specific news.
Vistagen Therapeutics, Inc. discloses operational outcomes and financial status (VTGN).
NeutralVistagen Therapeutics, Inc. has filed a Form 8-K detailing its results of operations and financial condition, which could lead to significant market reactions as investors assess the implications of the new information.